Clinical Trials · NCT03993132
A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- Boehringer Ingelheim
- Enrollment
- 26,774
- Start date
- Oct 2018
- Locations
- 1 site, Denmark
- Primary endpoint
- Incidence Rate of Expanded Major Adverse Cardiovascular Event (MACE) Composite Outcome - OT Analysis